Structure Therapeutics Inc.

NasdaqGM:GPCR Stock Report

Market Cap: US$1.5b

Structure Therapeutics Future Growth

Future criteria checks 2/6

Structure Therapeutics is forecast to grow earnings and revenue by 2.3% and 62.3% per annum respectively. EPS is expected to grow by 22.2% per annum. Return on equity is forecast to be -53.6% in 3 years.

Key information

2.3%

Earnings growth rate

22.2%

EPS growth rate

Pharmaceuticals earnings growth14.3%
Revenue growth rate62.3%
Future return on equity-53.6%
Analyst coverage

Good

Last updated22 Apr 2025

Recent future growth updates

Recent updates

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Mar 20

We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate

Mar 11
We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate

Structure Therapeutics: Competitive Data Is Emerging

Jan 03

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

Nov 25
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Oct 22

We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely

Aug 11
We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely

Structure Therapeutics: Yet Another Potential GLP-1 Entrant

Jun 14

Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape

Jun 05

Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation

Mar 10
Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation

Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans

Jun 29
Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans

Earnings and Revenue Growth Forecasts

NasdaqGM:GPCR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202717-322-299-2499
12/31/2026N/A-271-257-2019
12/31/202545-145-209-15311
12/31/2024N/A-123-118-117N/A
9/30/2024N/A-111-104-102N/A
6/30/2024N/A-100-105-103N/A
3/31/2024N/A-98-96-93N/A
12/31/2023N/A-90-82-79N/A
9/30/2023N/A-77-71-70N/A
6/30/2023N/A-66-60-60N/A
3/31/2023N/A-58-53-53N/A
12/31/2022N/A-53-46-46N/A
9/30/2022N/A-56-45-45N/A
12/31/2021N/A-44-33-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GPCR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GPCR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GPCR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GPCR's revenue (62.3% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: GPCR's revenue (62.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GPCR is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 00:32
End of Day Share Price 2025/05/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Structure Therapeutics Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Prakhar AgrawalCantor Fitzgerald & Co.
Zhuhong ChenChina Merchants Securities (HK) Co., Ltd